TetraKit had a great time attending the NOAR Europe annual meeting last week in Nantes!
Nadia Bom Pedersen, Ph.D. Felllow, presented her research in a session that focused on comparing the various promising strategies to prevent in vivo deastatination and increase efficacy and safety in targeted alpha therapy with ²¹¹At.
Andreas Ingemann Jensen, our co-founder and COO, gave a presentation on the TetraKit Platform, showcasing how seamless click chemistry enables the high-yield labeling of any targeting vector with any radionuclide, including of course ²¹¹At. The talk also featured new preclinical results, including excellent biodistribution of ¹³¹I-DualFAPi-5 and data demonstrating the TetraKit Platform’s observed superior performance over chelator-based analogues.
As part of our continued growth within the Greater Copenhagen “²¹¹At-node”, we now have access to a new astatine-211 lab at the University of Copenhagen, as well as preclinical facilities.
